Immunome, Inc. announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company?s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication. IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes. In preclinical testing, the antibodies exhibit combinatorial effects against multiple SARS-CoV-2 strains, including CDC variants of concern, and significantly reduces viral load in the lungs of hamsters infected with a SARS-CoV-2 reference strain. Immunome?s preclinical research demonstrates: The three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner. The first antibody binds to a sub-dominant epitope of the spike protein, which appears to be broadly conserved across all current and former SARS-CoV-2 variants of concern as well as other Betacoronaviruses and SARS-COV-1. The second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism. The third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop. As a cocktail, the three antibodies demonstrate enhanced anti-viral activity. Efficacious in pseudovirus neutralization against the CDC variant of concern, Delta. Shows equal or better activity against live virus in the reference and the variants tested to-date (Alpha, Beta and Gamma). Potent activation of phagocytosis and complement fixation ? known to be critical for in vivo treatment efficacy. In both treatment and prophylactic settings, at corresponding doses of up to 9 mg/kg, the cocktail potently reduced live viral titers by approximately 3.2 - 4 logs (or up to 10,000-fold) in the lungs of Syrian hamsters infected with SARS-CoV-2 virus. Published data for Sotrovimab (GSK and VIR Biotechnology), at 30 mg/kg, the highest dose tested in the prophylactic setting, show approximately a 2 log (or 100-fold) reduction in live viral titer in the lungs of Syrian hamsters infected with SARS-COV-2. This study was funded by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense?s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), in collaboration with the Defense Health Agency (DHA).